Drug Discovery in Microbial Metabolites #
28.4.4 Post Approval Research
Experimental studies and surveillance activities undertaken after a drug is approved for
marketing.
Clinical trials conducted after a drug is marketed (referred to as phase IV studies in the
United States) are an important source of information on as yet undetected adverse
outcomes, especially in populations that may not have been involved the premarketing
trials (e.g., children, the elderly, pregnant women) and the drug’s long-term morbidity
and mortality profile. Regulatory authorities can require companies to conduct Phase IV
studies as a condition of market approval. Companies often conduct post-marketing
studies even in the absence of a necessity to do so.
SUGGESTED READINGS
Allsop, A., Illingworth, R. 2002. The impact of genomics and related technologies on the search
for new antibiotics. Journal of Applied Microbiology, 92, 7-12.
Anon, 1993. Congress of the United States, Office of Technology Assessment. Pharmaceutical
R&D: Costs, Risks and Rewards: 1993; Washington, DC, USA. pp. 4-5.
Anon, 1999. From Test Tube to Patient: Improving Health Through Human Drugs Special
Report, Center Drug Evaluation and Research. Food and Drug Administration. Rockville,
MD, USA.
Austin, C. 2004. The Impact of the Completed Human Genome Sequence on the Development of
Novel Therapeutics for Human Disease. Annual Review of Medicine, 55, 1–13.
Bansal, A.K. 2005. Bioinformatics in the microbial biotechnology – a mini review Microbial Cell
Factories, 4, 4–19.
Beamer, L. 2002. Human BPI: One protein’s journey from laboratory to clinical trials. ASM News.
68, 543-548.
Behal, V. 2000. Bioactive Products from Streptomyces. Advances in Applied Microbiology. 47, 113–
156.
Bull, A.T., Ward, A.C., Goodfellow, M. 2000. Search and Discovery Strategies For Biotechnology:.
The Paradigm Shift. Microbiology and Molecular Biology Reviews, 64, 573-548.
Dale, E., Wierenga, D.E., Eaton, C.R. 2001. Processes of Product Develpoment. http://
www.allpcom/drug-dev.htm. Accessed on September 28, 2005 at 12.05 pm GMT.
Debouck, C., Metcalf, B. 2000. The Impact of Genomics on Drug Discovery. Annual Review of
Pharmacology and Toxicology, 40, 193–208.
Erlanson, D.A., Wells, J.A., Braisted, A.C. 2004. Tethering: Fragment-Based Drug Discovery.
Annual Reviews of Biophysical and Biomolecular Structure, 33, 199–223.
Fan, F., McDevitt, D. 2002. Microbial Genomics for Antibiotic Target Discovery. In : Methods in
Microbiology. Vol 33, Academic Press. Amsterdam the Netherlands, pp. 272–288.
Feling, R.H., Buchanan, G.O., Mincer, T.J., Kauffman, C.A., Jensen, P.R., Fenical, W. 2003.
Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a
marine bacterium of the new genus Salinospora. Angewandte Chemie International Edition 42,
355-357.
Manyak, D.M., Carlson, P.S. 1999. Combinatorial Genomics
TM
: New tools to access microbial
chemical diversity In : Microbial Biosystems: New Frontiers. C.R., Bell, M. Brylinsky, P.
Johnson-Green, (eds). Proceedings of the 8th International Symposium on Microbial Ecology
Atlantic Canada Society for Microbial Ecology, Halifax, Canada, 1999.